Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

Biodesix expands its Bio-Rad partnership to validate ddPCR cancer assays, starting with ESR1 mutation testing in breast ...

First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less ...

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific ...

Get Apollo Global's Q3 earnings preview, segment outlook, and fair value insights. See if now is the right time to invest.

You go out for drinks with friends, the evening gets out of hand, and the next day you're left with a pounding headache.

PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...

The latest update is out from Syndax Pharmaceuticals ( (SNDX) ).

Q3 2025 Earnings Call Transcript October 28, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.11, ...

The US Food and Drug Administration (FDA) has approved Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) ...

Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative ...